Latest Headlines

Latest Headlines

UPDATED: Pfizer, J&J kill PhIII program for key Alzheimer's drug

Pfizer and Johnson & Johnson have nixed development of one of the most closely watched drugs in their pipelines, bapineuzumab, after two Phase III clinical trials for the experimental Alzheimer's therapy ended in failure.

Can a new Pfizer find success in its long-struggling R&D division?

With Pfizer's animal-health unit now being spun out after a major retooling that has included deep cuts on the R&D side of the business, the big question now is whether Pfizer has a sensible research strategy in place as it concentrates its full attention on drug development.

Pfizer faces delay on tofacitinib as new data adds blockbuster luster

Pfizer's quest to gain an approval for a potential new blockbuster for rheumatoid arthritis has run into a speed bump at the FDA. Following a lopsided expert panel vote in its favor back in May, Pfizer CEO Ian Read told analysts on Tuesday that the agency is looking for some additional data analysis before it can come up with a formal decision on marketing the JAK inhibitor.

Analysts see sale of Elan to Biogen Idec as likely

No sooner had the world learned of disappointing clinical results on Elan Corp.'s ($ELN) Alzheimer's therapy, bapineuzumab, than pharma prognosticators started handicapping chances that it would be bought out by Biogen Idec ($BIIB).

A washout for Pfizer/J&J Alzheimer's drug in first PhIII study

Bapineuzumab failed to best placebo at easing symptoms of mild-to-moderate disease.

UPDATED: Pfizer, J&J Alzheimer's drug bapineuzumab flunks out in big PhIII

Pfizer ($PFE) and Johnson & Johnson ($JNJ) are reporting that in the first of four Phase III trials, bapineuzumab failed to outperform a placebo in moderating symptoms of mild-to-moderate Alzheimer's, a clinical train wreck that will only raise further doubts about the R&D track they laid down.

Investors offer grim odds of success for two big Alzheimer's programs

Mark Schoenebaum and the ISI group assessed the odds 146 prominent investors were giving to both Eli Lilly and the J&J/Pfizer drugs, solanezumab and bapineuzumab.

Elan boss: Climate improved for Alzheimer's drugs

The stakes are high for the experimental Alzheimer's drug bapineuzumab, which analysts give a low chance of proving effective against the memory-stealing disease.

TheStreet: A roundup of the top drug studies left in 2012

Any forward-looking student of the biotech industry will have to check out Adam Feuerstein's review in TheStreet of 22 Phase II and III clinical trials--21 drugs and one diagnostic test--which are expected to read out by the end of this year.

Genentech drug picked for pioneering $100M Alzheimer's trial

Investigators will test the drug in a region of Colombia where a particular genetic mutation is known to trigger the early onset of Alzheimer's.